Introduced in 2016, the POSEIDON (Patient-Oriented Strategies Encompassing Individualized Oocyte Number) classification was designed to enhance the prediction of ovarian response in In Vitro Fertilization treatment. But after ten years, what is the current clinical utility and future potential of the POSEIDON classification for women in assisted reproductive technology? A SOAR (Strengths, Opportunities, Aspirations, Results) analysis was conducted based on a literature review of studies published from 2016 to 2024 using the POSEIDON framework. Relevant articles were selected from an initial PubMed search, further refined with clinical filters and manual inclusion of key publications. A total of 29 articles were selected and analyzed using the SOAR strategic model to assess the classification’s strengths, limitations, potential clinical applications, and future prospects. The POSEIDON classification is now widely adopted internationally and enhances the stratification and comparability of women with low Assisted Reproductive Technology prognosis. It standardizes research cohorts beyond prior inconsistent definitions. Limitations include rigid cut-offs for age and ovarian markers, which may not reflect individual variability, and the grouping heterogeneity, as ~ 40% of patients with an initial poor response improve with adjusted stimulation. Evidence supporting tailored treatment across POSEIDON groups remains limited. Further prospective validation and subgroup refinement are warranted before routine clinical implementation. POSEIDON has made significant contributions to research standardization in low-prognosis assisted reproductive ART patients. However, translating it into daily clinical practice will require clarification of prognostic categories, individualized therapeutic implications, and integration of subgroups.
Carton et al. (Mon,) studied this question.